Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 205 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: levonorgestrel Clear all

Conditions: Heavy Menstrual Bleeding, Menorrhagia, Uterine Fibroids
Interventions: Levonorgestrel IUS, Tranexamic Acid; Drug
Lead sponsor: Shannon K. Laughlin-Tommaso; Other
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Residual Drug Amount of EE and LNG
Interventions: Twirla® (Levonorgestrel/Ethinyl Estradiol) Transdermal System; Drug
Lead sponsor: Insud Pharma; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Menorrhagia, Metrorrhagia, Medicated Intrauterine Devices
Interventions: Tamoxifen, Placebo (for Tamoxifen); Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Abnormal Uterine Bleeding, Unspecified, Uterine Bleeding Heavy
Interventions: EE 30mcg/LNG 150mcg, Placebo; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 14 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Sacramento, California • St Louis, Missouri

Conditions: Chronic Hepatitis B
Interventions: ABI-H2158, Itraconazole, Rifampin, Midazolam, Ethinyl Estradiol / Levonorgestrel, Esomeprazole, Placebo matching oral contraceptive; Drug
Lead sponsor: Assembly Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Epilepsy, Contraception
Interventions: levonorgestrel IUS; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)], Seasonique (LNG/EE and EE), Portia (LNG/EE); Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Healthy Adults
Interventions: PF-06882961, Atorvastatin, Midazolam, Levonorgestrel & Ethinyl Estradiol; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Oral Hormonal Contraceptive Use, Neural Activity, Mood, Hedonic Function
Interventions: Levonorgestrel/ethinyl estradiol, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older · Female only
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pregnancy Prevention
Interventions: Levonorgestrel 1.5 milligram, Meloxicam 15 milligram, calcium carbonate 750 milligram; Drug · Other
Lead sponsor: InnovaGyn, Inc.; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Contraception
Interventions: Levonorgestrel IUD (LCS, BAY86-5028), Yasmin (EE30/DRSP, BAY86-5131); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 29 Years · Female only
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 24
States / cities: Tucson, Arizona • La Mesa, California • San Diego, California + 8 more

Conditions: Obesity
Interventions: Levonorgestrel 1.5mg by mouth once; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Contraception
Interventions: Ulipristal Acetate, Levonorgestrel; Drug
Lead sponsor: Kimberly Myer; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 532 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 18
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 14 more

Conditions: Pregnancy Prevention
Interventions: Levonorgestrel 1.5mg, Meloxicam 15 mg, Placebo; Drug · Other
Lead sponsor: InnovaGyn, Inc.; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Ovarian Suppression
Interventions: Low dose formulation, High dose formulation; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Postpartum Period
Interventions: IUD, Diary; Device · Other
Lead sponsor: Baystate Medical Center; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Emergency Contraception
Interventions: Copper IUD, Levonorgestrel IUD; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cystic Fibrosis, Contraception
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 562 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 7 more

Conditions: Contraception
Interventions: LevoCept; Drug
Lead sponsor: Sebela Women's Health Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 279 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 16
States / cities: Berkeley, California • Los Angeles, California • Sacramento, California + 12 more

Conditions: Coronary Heart Disease
Interventions: Ethinyl Estradiol-Levonorgestrel combination, leuprolide acetate, Estradiol, Progesterone; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Endometrioid Endometrial Adenocarcinoma
Interventions: Glucagon-like peptide 1 receptor agonist; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Contraception
Interventions: Levonorgestrel IUD, copper IUD, etonorgestrel implant; Device
Lead sponsor: Tulane University School of Medicine; Other
Eligibility: 15 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Healthy Female Participants
Interventions: Zibotentan, EE/LNG; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Hormonal Contraception
Interventions: Depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant), Levonorgestrel IUD (Lng-IUD); Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 45 Years · Female only
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Atlanta, Georgia

Search by objective public record fields.

Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids

A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System

Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)

Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive

A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults

Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users

A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens

STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS

Contraceptive Hormone and Reward Measurement (CHARM Study)

Phase II Study of Ovulation in Obese Women

LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study

Effects of Obesity on Pharmacokinetics of the Levonorgestrel Emergency Contraceptive Pill

Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg

Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days

Obesity, Oral Contraception, and Ovarian Suppression

Bleeding Patterns and Complications After Postpartum IUD Placement: a Pilot Study

Study of the Copper IUD or Oral Levonorgestrel and the Levonorgestrel IUD for Women Seeking Emergency Contraception

Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis

Evaluation of the Efficacy and Safety of LevoCept

Relationship Between the Menstrual Cycle and Heart Disease in Women

A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia

Patient Compliance With Long-Acting Reversible Contraception Administration

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

Contraceptive Hormones, Immunity, and Microbiome Evaluation